Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Astrazeneca Plc (NY: AZN)
43.87 USD  -0.26 (-0.59%)
Official Closing Price  /  Updated: 4:36 PM EDT, Oct 18, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 1,654,232
Open 44.18
Bid (Size) 42.70 (2)
Ask (Size) 45.00 (2)
Prev. Close 44.13
Today's Range 43.67 - 44.20
52wk Range 35.30 - 46.22
Shares Outstanding 2,533,294,824
Dividend Yield 3.12%
Performance
YTD
+16.06%
+16.06%
1 Month
+1.72%
+1.72%
3 Month
+7.71%
+7.71%
6 Month
+13.07%
+13.07%
1 Year
+11.66%
+11.66%
Top News
More News
ImaginAb signs multi-party collaboration agreement with three global pharmaceutical companies to help further develop company's CD8 ImmunoPET technology
ImaginAb, Inc., a leading clinical-stage immuno-oncology imaging company, today announced the signing of a multi-party collaboration agreement with AstraZeneca (LSE/STO/NYSE: AZN), Pfizer Inc. (NYSE:... Read More
from PR Newswire
[Fam-] Trastuzumab Deruxtecan Granted FDA Priority Review for Treatment of Patients With HER2-positive Metastatic Breast Cancer
AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) today announced that the US Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for... Read More
from Business Wire News Releases
More News
Read More
AstraZeneca Shares Trade Higher After FDA Grants Breast Cancer Drug Priority Review
category Market News , News , Biotech , and 5 more.
from Benzinga
Healthcare Companies Seek Innovative Ways to Combat New Diseases
from PR Newswire
AstraZeneca Launches Signature STEM Program to Empower Students to Live Healthier Lives and Inspire Future Scientists
from Business Wire News Releases
FASENRA® (benralizumab) Approved in the US for Self-administration in a New Pre-filled Auto-injector, the FASENRA Pen™
from Business Wire News Releases
UPDATE 1-AstraZeneca breast cancer treatment gets FDA priority review
category companyNews
from Reuters: Company News
AstraZeneca gets FDA priority review for experimental breast cancer drug
category companyNews
from Reuters: Company News
Innate Pharma IPO: What You Need To Know
category Market News , Biotech , News , and 7 more.
from Benzinga
Are These 3 Beaten-Down Biotech Stocks Bargains Now?
category REGN , URGN , AZN , and 2 more.
from Motley Fool
IPO Outlook For The Week: Cancer Therapies And Protein Powders
category IPOs , Trading Ideas , IPHA , and 6 more.
from Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.